Terns Pharma

TERNS PHARMACEUTICALS INC

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Bernie's Concerns With Healthcare Costs

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AMRN

TERN

Top 3 Health Care Stocks You&#39;ll Regret Missing In Q4

Wall Street

Initiation

Analyst Ratings

ALMS

BRZE

ELVN

INTS

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Movers

Intraday Update

AIOT

APLT

BLCO

GYRE

IAUX

LUNR

VSCO

Applied Therapeutics, PowerFleet, VF Corp, Victoria&#39;s Secret And Other Big Stocks Moving Higher On Wednesday

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

Tern PLC

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Terna Energy SA

TERNA ENERGY SA UNSP/ADR by Terna Energy SA

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

Ternoa

Health Care

Press Releases

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Management

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

General

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Earnings

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Cormedix

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

scPharmaceuticals

Septerna

SIGA Technologies

SNDL

Third Harmonic Bio

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Terns Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga